Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aim, Coeptis, Cytosorbents, Epivax, Intravacc, Intrinsix.
Nearly six months after ditching its phase II/III COVID-19 vaccination study to chase a booster strategy, Inovio Pharmaceuticals Inc. is now ditching the heterologous booster. The decision to stop internally funding INO-4800 as a booster was made after sifting through data on global demand for COVID-19 vaccines, the condition of the market and Inovio’s own portfolio.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avrobio, Diamedica, Dyadic International, ITM Isotope Technologies München, Myeloid, Novo Nordisk, Reveragen, Santhera, Simcere.
Pfizer Inc. has divulged 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Novacyt, Radiaction, Transit Scientific.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Aquestive, Assertio, BMS, Ignyte, JW, Kissei, Obseva, Obsidian, Peak, Res Nova, Soligenix and Therapeutic Solutions.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Applied, Astrazeneca, Atai, Avrobio, Can-Fite, Cardiol, Gristone, Imaginab, Inotrem, Oblato, Quadriga, Seelos and Ultimovacs.
RSS
